Here are some facts that may help you decide whether to buy, hold, or sell. ZERO insider purchase - distribution continues ($29.5M extracted by the CTO). Continuous Dilution (SBC): Stock-Based Compensation remains a structural point of friction, with $265 million of SBC reported in the last quarter, continuing to dilute value for existing shareholders. Risk to the UK NHS Contract: Major concerns surround the non-renewal of the contract with the UK's National Health Service (NHS) (valued at approximately $440 million), as the UK Parliamentary Committee on Science, Innovation and Technology voted against its renewal by triggering the early exit clause in February 2027. Short interest is too low for a squeeze (3.14%). RSI at 72.83 is technically overbought. No Tier-1 fund accumulation was detected in July-August. The conclusion is simple: The stock is in an insider distribution phase despite a temporarily bullish flow options market. The complete absence of insider buying and the ultra-low short interest eliminate any potential for an asymmetric squeeze.